HIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...

The use of Pre-exposure Prophylasix (PrEP) has expanded significantly over the past few years contributing to reduction of new HIV infections.

Twice-a-year-PReP will only fulfill its potential if Medicaid takes decisive action to ensure it is accessible to the ...

Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...

The largest-ever study of women in sub-Saharan Africa zeroes in on the combination of bacterial vaginosis-associated bacteria ...

Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...

Contrary to popular belief, HIV remains a serious public health concern in Canada. New HIV diagnoses rose by a startling 25% ...

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Lencapavir, which is dosed only every six months, is highly effective at preventing HIV, but advocates worry its cost will blunt its impact.

Standard treatment of babies with HIV typically starts two to three months after birth and continues for decades. This new ...

Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has raised alarm over the increasing incidence of HIV among young ...